Table 1.

Clinical characteristics of study participants

PHSGelb CenterFHCRC
Cases/controls (n)1,438 (1,347)*/1,4623,714/—1,308/1,266
Deaths/long-term survivors (n)187/584250/15856/526
Age at diagnosis (n)1,4383,7141,308
    Mean (SD)70.5 (7.7)62.0 (8.2)59.9 (7.0)
Gleason (n)1,2703,4581,308
    <7 (%)51.341.157.3
    7 (%)33.537.433.1
    >7 (%)15.221.59.7
Pathologic stage (n)4691,452740
    T2 (%)72.767.571.3
    T3/T4 (%)27.332.528.7
PSA at diagnosis (n)68732781177
    Median (Q1, Q3)7.6 (5.4, 13.0)6.5 (4.7, 11.0)6.2 (4.6, 9.6)
  • * One thousand three hundred forty-seven cases were part of the PHS matched case-control study and included in the analysis for prostate cancer risk.